DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Description
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.
Eligibility
See official grant page for eligibility requirements
Industry Tags
About This Grant
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use. Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.
Funding Information
- Estimated Total Program Funding
- $7,000,000
- Expected Number of Awards
- 7
Eligibility Overview
This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements.
Federal grant opportunities like this one are typically open to a range of applicant types. Common eligible organizations include:
- Nonprofits and 501(c)(3) organizations
- Small businesses and startups (especially for SBIR/STTR programs)
- State, local, and tribal governments
- Colleges, universities, and research institutions
- Individuals (for select programs in education, arts, and research)
Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.
How to Apply
- 1
Review the full opportunity
Read the complete Notice of Funding Opportunity (NOFO) for this Defense Health Agency Contracting Activity - DHACA program on its official page (https://www.grants.gov/search-results-detail/362194).
- 2
Confirm eligibility
Check that your organization meets every requirement set by Defense Health Agency Contracting Activity - DHACA — applicant type, location, registration status, and any prior-award restrictions.
- 3
Prepare required documents
Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.
- 4
Submit before the deadline
This opportunity closes on September 30, 2026. Submit at least 48 hours early — portal systems are often slow near closing time.
Grant Writing Tips
Proposals for healthcare programs such as those from Defense Health Agency Contracting Activity - DHACA are competitive — these tips can strengthen your application:
- ✓Start your application at least 4 weeks before the deadline — rushed proposals score lower.
- ✓Tailor your needs statement to match the funder's stated priorities, using their exact language where possible.
- ✓Have a colleague outside your team review your budget narrative before submitting — fresh eyes catch errors reviewers penalize.
More Grants from Defense Health Agency Contracting Activity - DHACA
Frequently Asked Questions
Who is eligible for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?
This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements. Always confirm the full eligibility criteria on the official listing before applying.
How much funding does DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award provide?
The total estimated program funding for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award is $7,000,000.
When is the deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?
The application deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award is September 30, 2026. Submit at least 48 hours early to avoid last-minute portal issues.
How do I apply for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award?
Apply for DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award through the official grant page (https://www.grants.gov/search-results-detail/362194). Confirm your eligibility and prepare your application materials before the deadline.
Helpful Resources
Need help writing your grant application?
Try Instrumentl — Grant Writing Software →Starting a nonprofit to apply for grants?
Launch your nonprofit with Swyft Filings →GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.